Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment...
December 07, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has...
November 05, 2020 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update

Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common...
November 03, 2020 20:26 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing...
October 29, 2020 17:16 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing...
October 29, 2020 17:15 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Interim BPX-601 Data and Corporate Restructuring

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data...
September 30, 2020 16:07 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
September 28, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum to Participate in Two Upcoming Virtual Conferences

HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
August 06, 2020 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update

Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020 ...
July 31, 2020 16:08 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right